Cytokinetics price target raised to $96 from $88 at Citizens

Citizens analyst Jason Butler raised the firm’s price target on Cytokinetics (CYTK) to $96 from $88 and keeps an Outperform rating on the shares. Cytokinetics remains a top pick ahead of next quarter’s ACACIA-HCM results, with Q4 updates highlighting early progress in the MYQORZO launch for obstructive hypertrophic cardiomyopathy as prescribers complete Risk Evaluation and Mitigation Strategies certification and prescriptions begin to ramp, the analyst tells investors in a research note. While investor focus is shifting toward the upcoming Phase 3 non-obstructive HCM readout, conviction remains high heading into the data release, the firm adds.